Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Rev Infirm ; 71(285): 19-20, 2022 Nov.
Artigo em Francês | MEDLINE | ID: mdl-36599524

RESUMO

As after any surgical procedure, the spinal patient is transferred to the postoperative surveillance room. There, a nurse will closely monitor the patient's vital parameters. Particular vigilance is deployed to identify possible complications related to the operation, some of which are specific to scoliosis. The management of postoperative pain is also at the heart of the care.


Assuntos
Escoliose , Humanos , Escoliose/cirurgia , Escoliose/complicações , Dor Pós-Operatória , Complicações Pós-Operatórias
2.
Acta Anaesthesiol Scand ; 65(1): 40-46, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-32790073

RESUMO

BACKGROUND: The value of intravenous oxycodone compared to morphine remains controversial. The purpose of this trial was to compare opioid-related adverse events (ORAES) of intravenous oxycodone and morphine after total hip arthroplasty. METHODS: Patients scheduled for total hip arthroplasty were enrolled in this study of post-operative pain treatment with intravenous oxycodone or intravenous morphine (ratio 1:1). After surgery, patients received similar drug regimens for titration in the post-operative care unit followed by intravenous patient-controlled analgesia (PCA). The primary outcome was the number of patients with ≥1 ORAEs within the first 24 hours defined as either nausea, vomiting, respiratory depression, pruritus, urinary retention requiring evacuation, allergy, hallucinations. Secondary outcomes included pain scores and opioid consumption. RESULTS: The analysis included 238 patients with similar characteristics. There were 55 patients with at least one ORAEs in the oxycodone group vs 46 in the morphine group: 48% vs 40%, P = .19; relative risk = 1.22 (0.91:1.63). Intravenous oxycodone vs intravenous morphine requirements were respectively (median, IQR): 6 (0-11) vs 8 (0-12) mg (P = .06) for titration, 15 (8-26) vs 8 (5-16) mg (P = .001) for PCA, and 22 (12-37) mg vs 19 (11-28) mg for cumulated intravenous consumption (P = .048). During the first 24 hours, there was no difference in secondary outcomes (oxycodone vs morphine, respectively, in %): nausea (15 vs 13), vomiting (5 vs 5), urinary retention (20 vs 12) or pain scores. CONCLUSION: This study demonstrates that IV oxycodone did not significantly reduce ORAEs within the first 24 hours compared to similar ratio of IV morphine.


Assuntos
Analgésicos Opioides , Oxicodona , Analgesia Controlada pelo Paciente , Analgésicos Opioides/efeitos adversos , Método Duplo-Cego , Humanos , Morfina/efeitos adversos , Oxicodona/efeitos adversos , Dor Pós-Operatória/tratamento farmacológico
3.
Anaesth Crit Care Pain Med ; 39(3): 395-415, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32512197

RESUMO

OBJECTIVES: The world is currently facing an unprecedented healthcare crisis caused by the COVID-19 pandemic. The objective of these guidelines is to produce a framework to facilitate the partial and gradual resumption of intervention activity in the context of the COVID-19 pandemic. METHODS: The group has endeavoured to produce a minimum number of recommendations to highlight the strengths to be retained in the 7 predefined areas: (1) protection of staff and patients; (2) benefit/risk and patient information; (3) preoperative assessment and decision on intervention; (4) modalities of the preanaesthesia consultation; (5) specificity of anaesthesia and analgesia; (6) dedicated circuits and (7) containment exit type of interventions. RESULTS: The SFAR Guideline panel provides 51 statements on anaesthesia management in the context of COVID-19 pandemic. After one round of discussion and various amendments, a strong agreement was reached for 100% of the recommendations and algorithms. CONCLUSION: We present suggestions for how the risk of transmission by and to anaesthetists can be minimised and how personal protective equipment policies relate to COVID-19 pandemic context.


Assuntos
Analgesia/normas , Anestesia/normas , Betacoronavirus , Infecções por Coronavirus , Controle de Infecções/normas , Pandemias , Pneumonia Viral , Adulto , Manuseio das Vias Aéreas , Analgesia/efeitos adversos , Analgesia/métodos , Anestesia/efeitos adversos , Anestesia/métodos , COVID-19 , Teste para COVID-19 , Criança , Técnicas de Laboratório Clínico , Comorbidade , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/prevenção & controle , Infecções por Coronavirus/transmissão , Procedimentos Clínicos , Infecção Hospitalar/prevenção & controle , Infecção Hospitalar/transmissão , Desinfecção , Procedimentos Cirúrgicos Eletivos , Contaminação de Equipamentos/prevenção & controle , Acessibilidade aos Serviços de Saúde , Humanos , Controle de Infecções/métodos , Consentimento Livre e Esclarecido , Doenças Profissionais/prevenção & controle , Salas Cirúrgicas/normas , Pandemias/prevenção & controle , Isolamento de Pacientes , Equipamento de Proteção Individual/provisão & distribuição , Pneumonia Viral/prevenção & controle , Pneumonia Viral/transmissão , Cuidados Pré-Operatórios , Comitê de Profissionais , Risco , SARS-CoV-2 , Avaliação de Sintomas , Precauções Universais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...